Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
Cipla
Deloitte
Mallinckrodt
Federal Trade Commission
Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BYDUREON BCISE

« Back to Dashboard

Clinical Trials for Bydureon Bcise

Trial ID Title Status Sponsor Phase Summary
NCT00103935 Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes Completed Eli Lilly and Company Phase 2 Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.
NCT00103935 Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes Completed AstraZeneca Phase 2 Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.
NCT00308139 Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) Completed AstraZeneca Phase 3 A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.
NCT00877890 A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) Completed Eli Lilly and Company Phase 3 This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.
NCT00877890 A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) Completed AstraZeneca Phase 3 This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.
NCT01554618 Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes Recruiting AstraZeneca Phase 3 The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes.
NCT01664624 Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes Completed Takeda Phase 1 The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Bydureon Bcise

Condition Name

Condition Name for Bydureon Bcise
Intervention Trials
Type 2 Diabetes 7
Type 2 Diabetes Mellitus 5
Obesity 3
Diabetes Mellitus, Type 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bydureon Bcise
Intervention Trials
Diabetes Mellitus, Type 2 15
Diabetes Mellitus 13
Obesity 4
Atherosclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bydureon Bcise

Trials by Country

Trials by Country for Bydureon Bcise
Location Trials
United States 126
Israel 2
Italy 2
Mexico 2
Denmark 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bydureon Bcise
Location Trials
Texas 9
California 8
Florida 8
New York 7
Washington 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bydureon Bcise

Clinical Trial Phase

Clinical Trial Phase for Bydureon Bcise
Clinical Trial Phase Trials
Phase 4 9
Phase 3 7
Phase 2 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bydureon Bcise
Clinical Trial Phase Trials
Recruiting 15
Completed 10
Active, not recruiting 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bydureon Bcise

Sponsor Name

Sponsor Name for Bydureon Bcise
Sponsor Trials
AstraZeneca 8
Eli Lilly and Company 2
Vanderbilt University 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bydureon Bcise
Sponsor Trials
Other 26
Industry 13
NIH 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Baxter
Medtronic
Fuji
Cipla
Chinese Patent Office
Fish and Richardson
Merck
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.